• Goldman Sachs (GS) added Vertex Pharmaceuticals (VRTX) to its monthly US Director’s Cut list, a concentrated selection of high-conviction Buy-rated stocks.
  • Interactive Brokers (IBKR) was removed from the list, though the move appears driven by relative conviction rather than deteriorating fundamentals.
  • Vertex’s upcoming FDA decision and pipeline progress likely bolster its case, while IBKR’s strong quarter may already be priced in.

What Changed

Goldman Sachs updated its monthly US Director’s Cut list, swapping out Interactive Brokers for Vertex Pharmaceuticals. The list, which typically contains 20–25 high-conviction, Buy-rated US stocks, is designed to highlight names where the firm sees differentiated risk-adjusted return potential. The change is best read as a relative-conviction portfolio adjustment, not a downgrade of IBKR. Both companies are posting strong operating results, but Vertex’s near-term catalysts may strengthen its relative upside.

Why Vertex? A Pipeline of Catalysts

Vertex has delivered continued growth in its cystic-fibrosis franchise while building substantial non-CF opportunities in pain, gene therapy, kidney disease, and diabetes. The company’s Q2 2026 revenue rose 12% year over year to $3.334 billion, with net income of $1.100 billion. Management raised full-year 2026 revenue guidance to $13.1–$13.2 billion.

More importantly, Vertex has several upcoming milestones. The FDA accepted its application for povetacicept in IgA nephropathy under accelerated approval, with a target action date of November 30, 2026. Approval would mark Vertex’s first commercial nephrology product, diversifying revenue away from CF. Additionally, the company received clearance to test VX-017, a universal-donor islet-cell therapy for type 1 diabetes, and is progressing studies in polycystic kidney disease and APOL1-mediated kidney disease.

Vertex also announced an agreement to acquire Crinetics Pharmaceuticals (CRNX), a strategic move to broaden its pipeline. While this adds execution and integration risk, it underscores the company’s ambition beyond CF.

Why Remove Interactive Brokers?

Interactive Brokers reported a record Q2 2026, with revenue surging to $1.896 billion and net income of $1.338 billion. Commissions rose 30% year over year, and net interest income grew 23%. Client accounts jumped 34% to 5.19 million, and customer equity hit $930.3 billion. The broker’s operating margin was an impressive 77%, reflecting the scalability of its tech-led model.

Despite these strong numbers, IBKR’s stock trades near its 52-week high with a trailing P/E of 38.9. Goldman’s removal likely reflects a view that the stock’s strong momentum is already priced in, and that future growth may be more sensitive to market conditions, interest rates, and trading volumes. The firm continues to expand globally—recently adding access to the Bucharest Stock Exchange and enabling Brazilian futures trading for eligible non-Brazilian customers—but international expansion brings regulatory and currency risks.

A Relative Call, Not a Verdict

Goldman’s list changes are based on bottom-up fundamental analysis, not macro or thematic views. The addition of Vertex and removal of IBKR signal where the firm sees better relative risk-adjusted returns over the near term. For investors, it’s a reminder that list changes are about conviction levels, not necessarily a bearish call on the removed company.

As always, individual investors should consider their own research and risk tolerance. The financial landscape is dynamic, and these adjustments reflect a point-in-time view.

This article was generated with the assistance of AI and reviewed by an editor.